After four straight days of public meetings last week focused on the U.S. post-market surveillance system for devices, one thing is clear: regulators and the rest of the device community have a lot of work ahead to transform the system.
FDA wants to build on the current system, which largely relies on passive adverse event reporting and discrete, company-sponsored post-market surveillance studies, to establish an automated framework that catches troublesome...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?